- $59.55m
- $59.55m
- $0.03m
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:58 PM
Brief: Daxor Corp Reaffirms Focus On Blood Volume Analysis Technology
Brief: Daxor Corporation Submits 510(K) To FDA For Next-Generation Blood Volume Analyzer
Brief: Daxor Corporation Streamlines Regulatory Strategy For Groundbreaking Diagnostic Device
U.S. RESEARCH ROUNDUP- Blackstone, Coupang, Wells Fargo & Co
Brief: Daxor Corporation Acquires Volumex, Megatope From Its Iso-Tex Diagnostics
Brief: Daxor Awarded Additional New Patent For Smart Blood Volume Guidance Technology To Improve Treatment And Outcomes
Brief: New Randomized Controlled Trial Demonstrates The Efficacy Of Daxor’S BVA Guided-Care
Brief: Daxor Awarded New Patent for Remote Monitoring of Blood Volume
Brief: New Data From Banner University Medicine Demonstrating Effectiveness Of Bva-100® Use In Ambulatory Heart Failure Patients Presented At Heart Failure Society Of America Annual Scientific Meeting
U.S. RESEARCH ROUNDUP-Intuit, Rent the Runway, Tesla
U.S. RESEARCH ROUNDUP-Globus Medical, Philip Morris International, Vail Resorts
Brief: Pilot Randomized Controlled Trial Validates Daxor Bva-100® Diagnostic For Heart Failure Patients
Brief: Daxor Corp - New Data Validating Benefits Of Company's Bva-100 Diagnostic Blood Test
Brief: New Data Shows 85% Reduction In One-Year Mortality For Medicare Heart Failure Patients With Bva-Guided Care
Brief: Daxor Co Announces New Data From Duke Heart Validating Benefits Of Co's Bva-100 Blood Test In Optimizing Individualized Therapy For Heart Failure Patients
U.S. RESEARCH ROUNDUP- Fedex, Huntsman, Regeneron Pharmaceuticals
Brief: Daxor Corp Announces 49.4% Increase In Its Single-Use Diagnostic Kits Year-Over-Year And Further Acquisitions Of Its Bva-100 Blood Volume Analyzer By Leading Medical Centers Throughout U.S.
Brief: Daxor Corporation Announces Partnership With Medaxiom To Further Adoption Of Daxor’s Blood Volume Diagnostic